Company newsForm 8-K and release

Summit Therapeutics SMMT

Summit Therapeutics says FDA issued a complete response letter for ivonescimab

The company says the FDA determined the application cannot be approved in its present form without a statistically significant overall survival improvement.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

On November 15, 2026, Summit Therapeutics said the U.S. Food and Drug Administration issued a complete response letter for its biologics license application for ivonescimab, given with platinum-containing chemotherapy, for patients with locally advanced or metastatic non-small cell lung cancer who have received prior EGFR tyrosine kinase inhibitor therapy. The company said the letter indicates the application cannot be approved in its present form.

According to the company, the FDA determined that substantial evidence of effectiveness is not established without a statistically significant overall survival improvement. The company said the FDA indicated that the progression-free survival benefit, without a statistically significant overall survival benefit, does not support a positive benefit-risk profile in support of approval. The company said there are currently no FDA-approved regimens that have demonstrated a statistically significant overall survival benefit in this patient setting.

The company said the primary overall survival analysis for ivonescimab with chemotherapy showed a positive trend without achieving a statistically significant result. In a post-hoc analysis, longer-term follow-up of western patients showed a consistent overall survival benefit across regions, with a hazard ratio of 0.76 in the full population, Asian patients and western patients.

The application was supported by the HARMONi study, a global, randomized, double-blind Phase III clinical trial. The company said HARMONi met its progression-free survival primary endpoint, and that ivonescimab with chemotherapy showed an acceptable and manageable safety profile consistent with previous studies. Ivonescimab is not approved by any regulatory authority in the company's license territories, including the United States and Europe.

Robert W. Duggan, Chairman and Co-Chief Executive Officer, said the company is disappointed for patients and their families awaiting additional treatment options in this setting. Duggan said Summit Therapeutics would continue its clinical development program for ivonescimab.

Key facts

Announced
November 15, 2026
Regulatory action
Complete response letter
Application
Biologics license application for ivonescimab
Patient setting
Locally advanced or metastatic non-small cell lung cancer after prior EGFR TKI therapy
Post-hoc overall survival hazard ratio, full population
0.76

All SMMT news

Sources: Form 8-K filed November 16, 2026, and the company's release on Business Wire, November 15, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

Summit Therapeutics first, then the newest

All company news